SC-004 / AbbVie - LARVOL DELTA

SC004 - Stroke Council Underrepresented Racial and Ethnic Travel Grant and Bernard J Tyson Career Development Award Recognition Reception (ISC 2022) - No abstract available

Cardiovascular

[VIRTUAL] First-in-human study of SC-004, an antibody-drug conjugate targeting CLDN6/9, in patients with epithelial ovarian cancers (AACR-I 2020) - P1 | "Despite advancements with the development of PARP inhibitors and incorporation of bevacizumab, a clear unmet need remains for patients (pts) with recurrent EOC which is no longer considered appropriate for platinum-based chemotherapy (platinum-resistant). SC-004 demonstrated low tolerability with a side effect profile similar to other PBD-conjugated ADCs, along with insufficient evidence of activity to support continued investigation."

Clinical • P1 data • Endometrial Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers (clinicaltrials.gov) - P1; N=24; Terminated; Sponsor: AbbVie; Trial completion date: Jun 2021 ➔ Mar 2019; Active, not recruiting ➔ Terminated; Strategic considerations

Trial completion date • Trial termination

SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers (clinicaltrials.gov) - P1; N=8; Active, not recruiting; Sponsor: AbbVie; Recruiting ➔ Active, not recruiting; N=174 ➔ 8

Enrollment change • Enrollment closed

Newly added product (AbbVie Press Release) - P1, Ovarian Cancer

Pipeline update